Polyclonal T‐cell antibody showed no clear difference in mortality compared with no antibody induction (moderate certainty).
Polyclonal T‐cell antibody showed no clear difference in acute rejection grade II or higher compared with no antibody induction (moderate certainty).
Polyclonal T‐cell antibody showed no clear difference in infection compared with no antibody induction (moderate certainty).
Polyclonal T‐cell antibody showed no clear difference in bronchiolitis obliterans syndrome compared with no antibody induction (moderate certainty).
Polyclonal T‐cell antibody induction showed no clear difference in mortality compared with interleukin‐2 receptor antagonist induction (moderate certainty).
Polyclonal T‐cell antibody induction showed no clear difference in acute rejection compared with interleukin‐2 receptor antagonist induction (moderate certainty).
Polyclonal T‐cell antibody induction showed no clear difference in infection compared with interleukin‐2 receptor antagonist induction (moderate certainty).
Polyclonal T‐cell antibody induction showed no clear difference in bronchiolitis obliterans syndrome compared with interleukin‐2 receptor antagonist induction (moderate certainty).
Monoclonal antibody showed no clear difference in mortality Mortality at latest compared with polyclonal antibody (low certainty).
Monoclonal antibody showed no clear difference in acute rejection Acute rejection grade 3A or more verified by biopsy compared with polyclonal antibody (low certainty).
Monoclonal antibody showed no clear difference in infection Number of participants diagnosed with infection compared with polyclonal antibody (low certainty).
Monoclonal antibody showed no clear difference in cytomegalovirus infection Number of participants diagnosed with CMV… compared with polyclonal antibody (low certainty).
Monoclonal antibody showed no clear difference in post‐transplantation lymphoproliferative disorder Number of… compared with polyclonal antibody (low certainty).
Monoclonal antibody showed no clear difference in cancer Number of participants diagnosed with cancer compared with polyclonal antibody (low certainty).
Interleukin‐2 RA showed no clear difference in mortality Mortality at latest compared with polyclonal antibody induction (low certainty).
Interleukin‐2 RA may leads to higher acute rejection Acute rejection grade 3A or more verified by biopsy compared with polyclonal antibody induction (low certainty).
Interleukin‐2 RA showed no clear difference in infection Number of participants diagnosed with infection compared with polyclonal antibody induction (low certainty).
Interleukin‐2 RA showed no clear difference in cytomegalovirus infection Number of participants diagnosed with CMV… compared with polyclonal antibody induction (low certainty).
Interleukin‐2 RA showed no clear difference in cancer Number of participants diagnosed with cancer compared with polyclonal antibody induction (low certainty).